Cargando…
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
OBJECTIVES: To study the time-to-recurrence and duration of response in non-muscle invasive bladder cancer (NMIBC) patients, with a complete ablative response after intravesical apaziquone instillations. METHODS: Transurethral resection of bladder tumour(s) (TURBT) was performed in patients with mul...
Autores principales: | Hendricksen, Kees, van der Heijden, Antoine G., Cornel, Erik B., Vergunst, Henk, de Reijke, Theo M., van Boven, Erika, Smits, Geert A. H. J., Puri, Rajiv, Gruijs, Sigrid, Witjes, J. Alfred |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694322/ https://www.ncbi.nlm.nih.gov/pubmed/19214526 http://dx.doi.org/10.1007/s00345-009-0382-4 |
Ejemplares similares
-
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo(®) working party
por: Alfred Witjes, J., et al.
Publicado: (2009) -
Experimental rat bladder urothelial cell carcinoma models
por: Arentsen, Harm C., et al.
Publicado: (2009) -
A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model
por: Falke, Johannes, et al.
Publicado: (2018) -
Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer
por: Karsh, Lawrence, et al.
Publicado: (2018) -
Device-assisted intravesical therapy for non-muscle invasive bladder cancer
por: Hendricksen, Kees
Publicado: (2019)